💊 Aurobindo's Eugia Pharma Launches Pomalidomide Capsules in US Market | MCap 71,322.44 Cr - Eugia Pharma Specialities Limited, a subsidiary of Aurobindo Pharma, launched Pomalidomide Capsules (1 mg, ...

Aurobindo Pharma's subsidiary Eugia Pharma Specialities has launched generic Pomalidomide Capsules in the US, expanding its ...

Hyderabad: Aurobindo Pharma Limited on February 27, 2026 announced the completion of a US FDA inspection at Unit I of its wholly owned subsidiary Eugia Pharma Specialities Ltd. The inspection, ...

Eugia III resolution (in the backdrop of fresh observations) and the launch momentum across geographies would be key determinants, say analysts.

Aurobindo Pharma Limited on February 27, 2026 announced the completion of a United States inspection at its subsidiary's ...

Aurobindo's wholly owned subsidiary, Aurobindo Pharma USA, has entered into a collaboration and license agreement with an unnamed global pharma company for the development and commercialization of ...

Aurobindo Pharma’s subsidiary Eugia Pharma Unit-I in Telangana was inspected by the US FDA from February 16 to 27, 2026, ...

Eugia Pharma Specialities Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has launched Pomalidomide Capsules, 1 mg, 2 mg, 3 mg and 4 mg, in the US market.The product ...

Indian drugmaker Aurobindo Pharma plans to scale up production of Penicillin-G to more than 10,000 metric tonnes annually within the next 12 months. The Hyderabad-based pharmaceutical company ...

This initiative is part of Aurobindo Pharma’s broader strategy to strengthen its presence in international markets, particularly in the pharmaceutical sector. HYDERABAD, India — Aurobindo Pharma ...

Aurobindo Pharma plans to increase Penicillin-G production to over 10,000 metric tonnes annually in the next 12 months. The Hyderabad-based company's strategies aim to improve profitability through ...

Indian pharma leaders emphasize the need for innovation at scale, leveraging AI and collaborations to overcome industry ...